It was approved in the US in 2017 but EU regulators say Emmaus Life Sciences’ sickle cell disease therapy, Xyndari (oral glutamine), should not be allowed on the market in Europe.
Xyndari was one of six new medicines that were up for an opinion this week from the European Medicines Agency's scientific committee, the CHMP, on whether or not they should be approved for sale across the EU. Emmaus says it will seek a re-examination of the negative opinion
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?